Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

4DMT Presents Results Of 4D-150 SPECTRA Clinical Trial In DME And Regulatory Update

Author: Benzinga Newsdesk | July 31, 2025 03:25pm

4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level
4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control
Phase 3 dose (3E10 vg/eye) achieved clinically meaningful 78% reduction in treatment burden vs. projected on-label aflibercept 2mg Q8W
EMA aligned with proposed single Phase 3 clinical trial being acceptable for regulatory submission for 4D-150 in DME, consistent with previously announced alignment with FDA

Posted In: FDMT